Tekla Capital Management LLC - Q1 2019 holdings

$2.46 Billion is the total value of Tekla Capital Management LLC's 194 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .

 Value Shares↓ Weighting
CLDX ExitCelldex Therapeutics, Inc.$0-105,800
-100.0%
-0.00%
NCNA ExitNuCana plcsponsored adr$0-9,823
-100.0%
-0.01%
EIDX ExitEidos Therapeutics, Inc.$0-27,900
-100.0%
-0.02%
ONCE ExitSpark Therapeutics, Inc.$0-10,772
-100.0%
-0.02%
LXRX ExitLexicon Pharmaceuticals, Inc.sponsored adr$0-70,000
-100.0%
-0.02%
ACHN ExitAchillion Pharmaceuticals, Inc.$0-318,833
-100.0%
-0.02%
A ExitAgilent Technologies, Inc.$0-8,200
-100.0%
-0.02%
LMAT ExitLeMaitre Vascular, Inc.$0-27,150
-100.0%
-0.03%
ExitTakeda Pharmaceutical Co. Ltd.sponsored ads$0-19,200
-100.0%
-0.03%
ExitEgalet Corporationnote 5.50% 4/1/20$0-7,000,000
-100.0%
-0.03%
NITE ExitNightstar Therapeutics plcadr$0-98,929
-100.0%
-0.05%
DERM ExitDermira, Inc.$0-161,579
-100.0%
-0.05%
MTD ExitMettler-Toledo International Inc.$0-3,500
-100.0%
-0.08%
WAT ExitWaters Corporation$0-10,800
-100.0%
-0.09%
INOV ExitInovalon Holdings, Inc.$0-176,163
-100.0%
-0.11%
NVRO ExitNevro Corp.$0-68,760
-100.0%
-0.11%
INVA ExitInnoviva, Inc.$0-161,603
-100.0%
-0.12%
LOXO ExitLoxo Oncology, Inc.$0-24,595
-100.0%
-0.15%
STE ExitSTERIS plcshares$0-48,003
-100.0%
-0.22%
SHPG ExitShire plcsponsored adr$0-36,216
-100.0%
-0.27%
ExitAegerion Pharmaceuticals, Inc.note 2.00% 8/15/19$0-13,000,000
-100.0%
-0.42%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-05-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Gilead Sciences, Inc.41Q2 202312.4%
Amgen, Inc.41Q2 20235.8%
Biogen Inc.41Q2 20236.5%
Vertex Pharmaceuticals Incorporated41Q2 20235.3%
Regeneron Pharmaceuticals, Inc.41Q2 20239.1%
Illumina, Inc.41Q2 20233.4%
BioMarin Pharmaceutical Inc.41Q2 20232.9%
Teva Pharmaceutical Industries Ltd.41Q2 20233.2%
Neurocrine Biosciences, Inc.41Q2 20231.4%
McKesson Corporation41Q2 20232.2%

View Tekla Capital Management LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Tekla Capital Management LLC Q1 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Rallybio CorpJanuary 23, 20231,727,0674.6%
Zyla Life SciencesSold outJanuary 29, 202100.0%
ARCA biopharma, Inc.January 24, 202036,0682.3%
Verona Pharma plcFebruary 12, 20195,296,8454.9%
Alliqua BioMedical, Inc.February 12, 2018165,0003.3%
PIERIS PHARMACEUTICALS, INC.February 12, 20181,962,3804.4%
Intellipharmaceutics International Inc.February 13, 20152,184,0009.0%
HERON THERAPEUTICS, INC. /DE/February 14, 201420,598,6134.2%
MEDWAVE INCFebruary 14, 20121,277,3729.8%
MZT Holdings, Inc.February 14, 20122,553,4204.0%

View Tekla Capital Management LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2023-08-10
13F-HR2023-05-10
13F-HR2023-02-10
SC 13G/A2023-01-23
13F-HR2022-11-01
13F-HR2022-07-29
13F-HR2022-05-13
13F-HR2022-02-14
SC 13G2022-01-21
13F-HR2021-11-12

View Tekla Capital Management LLC's complete filings history.

Compare quarters

Export Tekla Capital Management LLC's holdings